The Filing Desk

CRISPR Therapeutics vs Dyadic International

CRISPR Therapeutics CRSP · Dyadic International DYAI · Biotechnology

CRISPR Therapeutics reported revenue of $4 million in fiscal 2025, about the same as Dyadic International's $3 million in fiscal 2025. CRISPR Therapeutics' revenue fell 90.6% in its latest year, and Dyadic International's fell 11.6%. CRISPR Therapeutics had an operating margin of -18933.7%, against -232.8% at Dyadic International.

Side by side

CRISPR TherapeuticsDyadic International
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Dec 31, 2025
Revenue$4M$3M
Revenue growth−90.6%−11.6%
Revenue growth a year, last 5 years38.0%14.1%
Gross margin—24.9%
Operating margin−18,933.7%−232.8%
Net margin−16,569.8%−238.3%
Free cash flow−$346M—
Free cash flow margin−9,855.5%—
Return on capital——
Net debt to EBITDA——
Dividends and buybacks$0M$0M
Change in diluted share count6.6%11.3%
Last close$38.93$0.31
P/E at the last close——
Insider trades, last 12 monthssold $14.5 millionsold $124,914
Piotroski F-score——
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
CRISPR TherapeuticsDyadic International
Operating margin
Percent of revenue
CRISPR TherapeuticsDyadic International
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
CRISPR TherapeuticsDyadic International

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the CRISPR Therapeutics and Dyadic International pages.